Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl

Eur J Prev Cardiol. 2023 Nov 30;30(17):1935-1938. doi: 10.1093/eurjpc/zwac212.

Authors

Jedidiah I Morton^{1

2

3}, Danny Liew⁴, Stephen J Nicholls⁵, Zanfina Ademi¹

Affiliations

¹ Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
² School of Public Health and Preventive Medicine, Monash University, Australia.
³ Baker Heart and Diabetes Institute, Australia.
⁴ Adelaide Medical School, University of Adelaide, Australia.
⁵ Victorian Heart Institute, Monash University, Australia.

PMID: 36125211
DOI: 10.1093/eurjpc/zwac212

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cardiovascular Diseases* / drug therapy
Eicosapentaenoic Acid / adverse effects
Eicosapentaenoic Acid / analogs & derivatives
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypertriglyceridemia*
Triglycerides

Substances

eicosapentaenoic acid ethyl ester
Eicosapentaenoic Acid
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides

Grants and funding